Table 1 Characteristics of patients with Muckle-Wells syndrome (MWS) treated with interleukin-1-blocking therapy
From: Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens
| Â | Anakinra cohort n= 12 | Canakinumab cohort n= 14 |
|---|---|---|
Demographics | Â | Â |
Male/female patients | 3:9 | 5:9 |
% females | 75 | 64 |
Median age at MWS diagnosis in years (range) | 19.0 (3.0 to 65.5) | 27.0 (3.0 to 72) |
Median age at anti IL-1 therapy in years (range) | 21.0 (3.0 to 66.5) | 29.0 (4.0 to 74.5) |
NLRP3 mutation | Â | Â |
Mutation subtypes: Â Â Â E311K No (%) Â Â Â T348M No (%) Â Â Â V198M No (%) | 7/12 (58%) 3/12 (25%) 2/12 (17%) | 10/14 (71%) 2/14 (14%) 2/14 (14%) |
Follow-up | Â | Â |
Median follow-up in months (range) | 52 (23 to 115) | 50 (23 to 110) |